Advanced Solid Tumor Clinical Trials in Houston, Texas

51 studies are recruiting for advanced solid tumor in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. SW-682 in Advanced Solid Tumors

   This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after a…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   U.T. MD Anderson Cancer Center, Houston, Texas

   Locations

   8 in total

   Run by

   SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

   See if you can join NCT06251310 on ClinicalTrials.gov

2. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oncology Consultants, Houston, Texas

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

3. Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

   The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with zedoresertib in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   #1001, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   26 in total

   Run by

   Debiopharm International SA

   See if you can join NCT04855656 on ClinicalTrials.gov

4. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

5. A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

   This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric can…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   96 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06172478 on ClinicalTrials.gov

6. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

7. An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

   This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), in combination with standard of c…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas Md Anderson Cancer Center, Houston, Texas

   Locations

   101 in total

   Run by

   BeOne Medicines

   See if you can join NCT06589596 on ClinicalTrials.gov

8. Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

   This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas - MD Anderson Cancer Center, Houston, Texas

   Locations

   27 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT05898399 on ClinicalTrials.gov

9. First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

   This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas M.D. Anderson Cancer Center, Houston, Texas

   Locations

   61 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05875168 on ClinicalTrials.gov

10. BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

    This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growt…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    61 in total

    Run by

    BeOne Medicines

    See if you can join NCT06120283 on ClinicalTrials.gov

11. Study of APR-1051 in Patients With Advanced Solid Tumors

    The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center (MDACC), Houston, Texas

    Locations

    7 in total

    Run by

    Aprea Therapeutics

    See if you can join NCT06260514 on ClinicalTrials.gov

12. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

    This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytologically confirmed solid tumors that are advanced (i.e., either me…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    77 in total

    Run by

    BioNTech SE

    See if you can join NCT07070232 on ClinicalTrials.gov

13. Anti-GD2 ADC M3554 in Advanced Solid Tumors

    The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    11 in total

    Run by

    EMD Serono Research & Development Institute, Inc.

    See if you can join NCT06641908 on ClinicalTrials.gov

14. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

15. A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

    This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    28 in total

    Run by

    BeOne Medicines

    See if you can join NCT05981703 on ClinicalTrials.gov

16. A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

    This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    15 in total

    Run by

    BeOne Medicines

    See if you can join NCT07181681 on ClinicalTrials.gov

17. An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    32 in total

    Run by

    BeOne Medicines

    See if you can join NCT07222267 on ClinicalTrials.gov

18. A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

    The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    23 in total

    Run by

    BeOne Medicines

    See if you can join NCT07226349 on ClinicalTrials.gov

19. SLV-154 Treatment of Advanced Cancers

    This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    12 in total

    Run by

    Solve Therapeutics

    See if you can join NCT06771219 on ClinicalTrials.gov

20. A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

    A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer harboring KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas

    Locations

    16 in total

    Run by

    Blueprint Medicines Corporation

    See if you can join NCT07629960 on ClinicalTrials.gov

21. Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

    This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    17 in total

    Run by

    Aulos Bioscience, Inc.

    See if you can join NCT05267626 on ClinicalTrials.gov

22. A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

    A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    Locations

    21 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06859762 on ClinicalTrials.gov

23. Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in parti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas Md Anderson Cancer Center, Houston, Texas

    Locations

    34 in total

    Run by

    BeOne Medicines

    See if you can join NCT06598800 on ClinicalTrials.gov

24. ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

    Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    14 in total

    Run by

    Adcendo ApS

    See if you can join NCT06597721 on ClinicalTrials.gov

25. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Locations

    33 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06561685 on ClinicalTrials.gov